APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback